Genocure Conducts Medical Volunteer Work With Opus Clinic
페이지 정보
작성자Admin 조회 37 views 작성일 2024-11-18본문
Genocure Conducts Medical Volunteer Work With Opus Clinic
- Genocure conducts medical volunteer work with Opus Clinic,
which is operating as a PDRN center of Genocure, as a ESG activity at Banghari, Gapyeong -
July. 17, 2024
A regenerative biomaterial specialized company, Genocure Co., Ltd (CEO Oh Bo-gyeong, www.genocure.co.kr), conducted a volunteer work and a workshop with ‘Opus Clinic’(Doctor Choi Young-min), a specialized clinic for lifting and medical skincare, to participate an ESG activity that involves companies and hospitals together.
Genocure is a bio venture startup, that is now entering the global regenerative medical market through supply of PDRN, a raw material for pharmaceuticals, medical devices, and cosmetics, upon the technology of extracting and producing PDRN of high purity and the research and development on the next-generation PDRN. It has been operating a ‘PDRN Center’ at ‘Opus Clinic’, which has been well-received for its lifting procedures and medical skincare for over 10 years in LA, USA, to promote the efficacy of PDRN and related products since last June.
‘Opus Clinic’ is headquartered in LA, USA, ‘Yonsei by Jeunex Clinic’ which opened in 2013. It provides specialized lifting and medical skin care services such as thread lifting and face and body care. It’s now presenting services and derma-care products that allow you to experience the efficacy of PDRN in a practical way, combining the clinic’s know-how accumulated over time with Genocure’s PDRN. Doctor Choi Young-min of Opus Clinic stated that the clinic has established a strategic partnership with Genocure.
Regarding this, Oh Bo-gyeong, CEO of Genocure, delivered that through medical volunteer work with Opus Clinic, she realized the importance of a corporation’s social responsibility once again. She added, “Genocure will implement various methods that can realize the ESG value of the company, thereby fulfilling the social responsibility along with the company’s growth.”